occur through blood transfusion and organ transplantation, universal screening for WNV RNA was implemented in 2003 for blood donations in the United States [4] [5] [6] . Screening data have shown that WNV infection in the general population remains rare, with seropositivity being found in ∼1 in 10,000 blood donors [7, 8] .
It is estimated that most WNV-infected individuals remain asymptomatic, with 20%-30% developing symptoms after a 2-14-day latency period [9] . Clinical features can range from mild flu-like symptoms (West Nile fever [WNF] ) to more severe West Nile neuroinvasive disease (WNND) [9] . Clinical features of WNF typically include fever, headache, fatigue, skin rash, swollen lymph glands, and eye pain (http:// www.cdc.gov). WNND manifests primarily as meningitis, encephalitis, and/or acute-flaccid paralysis, and associated severe clinical features commonly include diarrhea and vomiting, generalized weakness, bone and joint pain, severe muscle aches, tremors, seizures, new cognitive difficulty, and changes in mental status [9] . Thus, outcome of WNV infection is heterogeneous, and identification of the risk factors that affect outcome is an important goal.
In a mouse model of WNV disease, chemokine receptor CCR5 was found to be a strong host defense factor, with CCR5-deficient mice displaying markedly increased viral titers in the central nervous system and experiencing a higher mortality rate [10] . We have extended these findings in mice to humans by demonstrating a strong epidemiologic association between symptomatic WNV disease and homozygosity for a common, complete loss-of-function mutation named CCR5D32 in the chemokine receptor gene CCR5 ( ; odds ratio [OR], 4.2; P ! .001 95% confidence interval [CI], 2.1-8.3) [11, 12] . Although these studies showed a strong, reproducible association with WNVpositive patients with a clinical diagnosis of WNF or WNND from 4 geographically and temporally distinct US collections, they were unable to distinguish whether the association was with susceptibility to infection or with severity of clinical presentation. Our previous analyses were retrospective; they did not include individuals who remained asymptomatic or mildly symptomatic, did not record specific clinical symptoms, and were not designed to capture patients in early stages of infection. To address these questions, we retrospectively screened a nonconcurrent prospective cohort of blood donors from the American Red Cross (ARC) to identify asymptomatic and symptomatic WNV-positive individuals and compared CCR5D32 genotypic frequencies with infection and self-reported symptoms associated with WNV disease.
MATERIALS AND METHODS
Study populations. The study was approved by the Office of Human Subjects Research of the National Institutes of Health. All blood samples from random blood donors collected by the ARC from May 2003 through July 2008 were tested for reactivity to a WNV-nucleic acid amplification test (NAT) as described elsewhere [7, 13] . Upon identification of a WNV NAT reactive donation, donors were contacted for enrollment and/ or participation in the follow-up study, which included a questionnaire regarding symptoms. Prior to learning their true WNV infection status, all donors were administered a followup, standardized check-box questionnaire by trained personnel in the course of an in-person interview. Blood donors that had reactive test results on the initial screening were further tested, and their cases were defined as either WNV true positive (656 cases), if repeat WNV NAT and WNV-specific antibody test results were positive, or WNV false positive (431 control participants) if repeat WNV NAT and WNV-specific antibody test results were negative. The questionnaire provided information for all donors regarding age, race, sex, date of sample collection, and the presence or absence of 15 listed symptoms consistent with WNV infection and other self-reported symptoms occurring during the 2 weeks following blood donation. The 15 listed symptoms were fever, chills, headache, painful eyes, severe muscle pain, swollen glands, new rash, seizures, tremors, new cognitive difficulty, generalized weakness, joint pain, bone pain, vomiting or diarrhea, and abdominal pain. All blood components associated with a donation specimen that were reactive on the initial WNV NAT were quarantined, and the plasma unit was retrieved for additional testing.
DNA isolation and genotyping. DNA from 250 mL of index plasma samples was purified and eluted into 100 mL of recommended buffer using NucliSENS EasyMAG technology (Biomerieux). Genotyping was performed by methods described elsewhere [12] . Briefly, 2 mL of DNA was amplified by polymerase chain reaction (PCR) using primers that flank the site of the 32 base pair (bp) deletion: 5 -TGTTTGCGTCTCTC-CCAG-3 and 5 -CACAGCCCTGTGCCTCTT-3 . PCR products were analyzed by electrophoresis on a 3.0% agarose/tris-borate EDTA gel with known wild-type CCR5 and CCR5D32 amplicon controls (233 and 201 bp, respectively) and visualized with Gelstar (Cambrex) DNA staining. Each sample was tested in 2 independent PCR reactions, and results were concordant, as determined by 2 independent investigators. Statistical analysis. ORs and 95% CIs were calculated using a recessive genetic model (Graphpad Software). Statistical significance was determined by a 2-sided Fisher exact test. Hardy-Weinberg equilibrium was judged using a x 2 test and 2 degrees of freedom to calculate expected frequencies of the 3 genotypes. The 2-sided unpaired Student t test was used to calculate statistical significance of the number of symptoms reported according to genotype. Logistic regression analysis was used to estimate the probability of homozygosity as a function of the square root of the number of symptoms. A likelihood ratio test was used to test the null hypothesis.
RESULTS
From May 2003 through July 2008, a total of 34,766,863 blood donations were screened by the nationwide WNV blood screening program of the ARC by WNV NAT. As shown in Figure  1 , initial screening revealed 1892 donations to be reactive. Because initial WNV NAT screening has a high false positivity rate, all 1892 positive donations were also subjected to serological testing and a follow-up WNV NAT to determine true or false WNV positivity. Of the 1892 donations identified as potentially positive, 1065 were confirmed as WNV true positive (WNV-positive cases, 1 in 32,645 blood donors); the remaining 827 donations were WNV false positive (WNV-negative control participants), defined as negative by both serological testing and a follow-up WNV NAT. On the basis of sample availability and the inclusion criteria for this study (defined as self-reported white/non-Hispanic, information available regarding age and sex, and completed questionnaire), we were able to analyze The characteristics of the study subjects, including symptoms experienced within 2 weeks after donation, are shown in Table  1 . Cases and control participants were similar in age, but cases were more likely to be male, as observed elsewhere [9] . The frequency of individuals who reported no symptoms on the questionnaire after donation was significantly greater among cases than control participants (75.6% vs 33.6%;
; OR, P ! .001 5.42; 95% CI, 4.15-7.09). When each symptom was evaluated separately, cases were more likely than control participants to report symptoms (Table 1) , as expected and as reported elsewhere [13] .
To test whether CCR5D32 is associated with susceptibility to WNV infection, we compared genotypic frequencies of cases with control participants. Within these groups, the CCR5 genotypes were in Hardy-Weinberg equilibrium ( and .16, P p .13 respectively). Among control samples, 10 (2.4%) of 422 were CCR5D32 homozygotes (Table 2 ). This value was identical to the frequency of CCR5D32 homozygotes observed in WNVpositive cases (15 of 634 cases; 2.4%). Thus, CCR5D32 homozygosity is not associated with WNV infection per se. It is important to note that there is a fundamental difference in the way participants were identified in the present study versus in our previous studies that reported an association between CCR5D32 homozygosity and symptomatic WNV disease. The previous studies selected for individuals seeking medical attention for symptomatic disease, whereas the ARC donors in the present study were accrued as voluntary blood donors independent of symptoms. Therefore, we next hypothesized that CCR5D32 homozygosity is associated with symptoms in early WNV infection, which the design of the present study uniquely allowed us to test by examining the distribution of symptoms according to genotype. The symptoms evaluated here are based on a previously published and validated follow-up questionnaire [13] that was administered to all individuals whose samples were reactive on the initial WNV NAT screening test (both cases and control participants) prior to learning their WNV infection status. As shown in Figure 2A , patients who were homozygous for CCR5D32 experienced more symptoms (5.47 symptoms), on average, than did those patients who were heterozygous (2.81 symptoms) or homozygous (3.05 symptoms;
) for wild-type CCR5. This increase in symptom num-P p .002 ber was not observed among the participants who were homozygous for CCR5D32 identified in the WNV-negative control group ( ; Figure 2A ) and was not related to age. P p .49 The mean ages ‫ע(‬ SD) for WNV-seropositive CCR5 patients with wild-type alleles ( ), heterozygous for CCR5D32 48.5 ‫ע‬ 14 ( ), and homozygous for CCR5D32 ( ) were 48.0 ‫ע‬ 13 47.5 ‫ע‬ 11 very similar. To further understand the relationship between CCR5D32 homozygosity and symptoms, we stratified the ARC cases into 2 groups, those with symptoms and those without symptoms. As shown in Table 2 , we identified no patients ho- NOTE. Data are percentage of participants, unless otherwise indicated. Data on symptoms experienced 2 weeks after blood donation were self-assessed and based on a face-to-face interview and questionnaire. CI, confidence interval; OR, odds ratio. mozygous for CCR5D32 among the 169 asymptomatic WNVpositive cases, which was less than expected on the basis of the overall frequency observed in the ARC cohort (4.4 cases homozygous for CCR5D32 were expected) and significantly decreased when compared with the frequency observed among the 280 asymptomatic WNV-negative control participants, where 7 patients homozygous for CCR5D32 were identified ( ). Compared with cases who developed symptoms (465 P ! .05 patients), a significant difference was observed in the frequency of this genotype (0% vs 3.2%; ) ( Figure 2B ). No sig-P p .015 nificant differences were observed when the asymptomatic and symptomatic control participants were compared ( ), or P 1 .99 when symptomatic WNV-positive cases were compared with symptomatic WNV-negative control participants ( ). P p .78 However, a logistic regression analysis plotting the predicted probability curve of CCR5D32 homozygosity as a function of the number of symptoms identified a significant positive correlation ( ) for WNV-positive cases ( Figure 2C ) but P p .002 not for WNV-negative controls (not shown).
To understand whether any specific symptoms were associated with CCR5D32 homozygosity, we evaluated the symptom prevalence among the cases homozygous for CCR5D32 versus cases with a wild-type allele. As shown in Table 3 An unpaired Student t test was used to calculate significance of the difference between CCR5D32 homozygotes versus CCR5D32 heterozygotes and CCR5 wild-type individuals. +, CCR5 wild-type allele; D32, CCR5D32 allele. B, Frequency of CCR5D32 homozygosity among WNVpositive cases or WNV-negative control participants with no symptoms was compared with that among individuals reporting у1 symptom. C, The predicted probability curve (solid line) along with upper and lower 95% confidence intervals (dotted lines) of CCR5D32 homozygosity is plotted as a function of the number of symptoms for WNV-positive cases.
could be associated with neurologic disease, were increased, although only the first reached statistical significance.
DISCUSSION
In this study, we show, using samples collected from random blood donors, that CCR5 deficiency is not associated with increased susceptibility to infection but rather with a more aggressive early clinical presentation, with a higher frequency of individual symptoms and more total symptoms, compared with CCR5-sufficient individuals. In fact, we found no individuals who were WNV positive and homozygous for CCR5D32 who did not report symptoms. CCR5D32-homozygous individuals with WNV infection were more likely to present with multisystem symptomatology, including lymphadenopathic, neurologic, and gastrointestinal symptoms. The role of CCR5D32 homozygosity as a predictor of severity of clinical presentation is consistent with the hypothesis that functional CCR5 is critical for control of WNV in humans.
It is important to note that the present study is a retrospective analysis of a nonconcurrent prospective cohort, with the WNVpositive cases identified before the onset of symptoms, whereas our previous studies of WNV-related symptoms were retrospective and selected for individuals seeking medical attention for clinical manifestations of WNV disease. The current study also captures a wide range of clinical presentation of initial infection, including individuals who remained healthy and those who experienced symptoms. Thus, unlike our previous study that analyzed patients with more advanced disease, the current study evaluates WNV-infected individuals at an early stage of disease. The current study design allowed us to directly compare CCR5D32 frequency among symptomatic WNV-positive cases to both asymptomatic WNV-positive cases and uninfected WNV-negative control participants and therefore to evaluate the role of CCR5D32 in both susceptibility to infection and severity of disease. Our data show no evidence for increased susceptibility or symptoms associated with CCR5D32 heterozygosity, because frequency of heterozygosity was similar between cases and control participants (Table 2) , and individuals who were CCR5D32 heterozygotes were identical to individuals homozygous for wild-type CCR5 with respect to the number of symptoms experienced (Figure 2A) , and individual symptom prevalence (data not shown). These data suggest that in CCR5D32 heterozygotes, normal CCR5 expression is in excess relative to what is needed for normal host defense against WNV. The mechanism by which CCR5 functions at the biochemical level in vivo is not known and may involve dimerization with another chemokine receptor. Potential partners, on the basis of previously reported biochemical data, include CXCR4 and CCR2 [14, 15] .
The frequency of CCR5D32 homozygosity observed among the WNV-false-positive control participants (2.4%) was slightly NOTE. Values were calculated by dividing the number of individuals with a certain genotype reporting the symptom by the total number of individuals with that genotype. P values were not corrected for multiple testing, because there is only 1 independent hypothesis. +, CCR5 wild-type allele; D32, CCR5D32 allele; CI, confidence interval; OR, odds ratio.
a CI was calculated using the exact method for tremors because of small numbers.
elevated, compared with previous reports of the frequency of this genotype in white individuals in the United States, which range from 0.7% through 1.7% [11, [16] [17] [18] [19] [20] [21] . It is important to note that the study populations tested in these previous studies were sampled from 1 region or city of the United States, whereas the control population tested in the current study is the first, to our knowledge, to evaluate the frequency of CCR5D32 homozygosity on the basis of large-scale sampling of the entire nation. In any case, the frequency we found is only 0.7% greater than the upper range previously reported. Other virtues of the control group used in the present study are that the participants (1) were temporally and geographically matched to the cases, (2) were accrued in the same manner as the cases, and (3) had filled out and submitted the same symptom questionnaire as the cases (Figure 3 ). The only other potential control group available from among the ∼35 million donations is one composed of those who had negative screening results at the time of blood donation (true negatives). However, these donors would not have filled out a questionnaire, because they were nonreactive according to the initial WNV NAT screening test and thus were not enrolled in the WNV follow-up study. Even if these patients had been enrolled in the study, they would have answered the questionnaire regarding symptoms with the knowledge that they were WNV negative, which might bias the response regarding symptoms. It is also important to consider potential limitations to our study. First, there may be recall bias, because all individuals were aware of their potential infection with WNV and may have been more likely to report symptoms. However, both cases and control participants answered the questionnaire before learning the results of their true WNV infection status, and thus a similar bias would be expected. Because the latency period before symptom onset has been estimated to be 2-14 days, it is possible that a donor could have tested positive for WNV but already have experienced the majority of their symptoms, causing an underreporting of symptoms on the questionnaire for this group. Second, evaluation of symptoms was based on participant response, rather than on objective measurements, and therefore could be imprecise. Finally, our results do not address the mechanism of action of CCR5 during WNV pathogenesis. Our study involving WNV in an excellent mouse model has suggested that it works, in part, at the level of leukocyte trafficking, at least for neuroinvasive disease; however, mechanisms in humans could differ [10] .
WNV infection is the first human disease for which normal CCR5 has clearly been shown to be beneficial [11, 12, 22] . Prior to these studies, CCR5-deficient individuals were believed to have minimal, if any, health defects as a result of their deficiency [23] . In contrast, they were well known to have strong resistance to human immunodeficiency virus (HIV) infection, because normal CCR5 is used as a critical coreceptor for cell entry. This finding led to the development of Maraviroc, an effective CCR5 antagonist used in the treatment of HIV/AIDS [24] . Although Maraviroc had an excellent safety profile in clinical trials, be- cause it is now marketed and used on a larger scale, it will be important to maintain a high index of suspicion in HIV-infected individuals treated with Maraviroc who present with signs and symptoms compatible with WNV infection, particularly because these patients are already immunocompromised. Our results suggest that, if a patient who is currently taking Maraviroc does test positive for WNV infection or displays the characteristic symptoms during an outbreak, that the drug should be withheld until the infection is cleared. A more general caution regarding WNV risk may apply to any CCR5 blocking agent that might be developed and any disease in which it might be used. It will also be interesting to investigate the susceptibility of CCR5-deficient individuals to other types of flaviviruses. In this regard, CCR5D32 homozygosity has recently been associated in 1 study with increased susceptibility to tick-borne encephalitis virus [25] .
Although our study specifically highlights the importance of a single genetic risk factor in a specific infectious disease, it also illustrates the power of large-scale databases to answer important clinical questions regarding diseases in humans, particularly for rare diseases and/or rare genetic mutations.
